Marksans Pharma arm gets marketing authorisation for Cyanocobalamin 50mg film coated tablets from UK MHRA

Mumbai: Marksans Pharma Limited has announced that its wholly owned subsidiary Relonchem Limited has received Marketing Authorisation for the product Cyanocobalamin 50mg film coated tablets from UK MHRA.

Medical Dialogues team had earlier reported that the Company had received final approval from USFDA for its Abbreviated New Drug Application (ANDA) for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg (OTC).

Read also: Marksans Pharma bags USFDA nod for Esomeprazole Magnesium Delayed Release Capsules

Marksans Pharma Limited headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities located in India, USA and UK are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. The company's product portfolio spreads over major therapeutic segments of CVS, CNS, Antidiabetic, Pain Management, Gastroenterological and Antiallergies. The company is marketing these products globally.

Read also: Marksans Pharma Mucus loosening drug Guaifenesin ER bags USFDA okay